Recent Company News

• 10:59 PM ET Sep 13, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 04:02 AM ET Sep 29, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 09:23 PM ET Sep 28, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight +1.12%; Hang Seng Futures +0.11%

• 08:09 PM ET Sep 28, 2026
  

  AstraZeneca submit US NDA for Orpathys/Tagrisso in MET-driven EGFR-mutated NSCLC (HK$22.50, 0.00)

• 09:19 PM ET Sep 27, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (0.64%); Hang Seng Futures (0.86%)

• 08:01 PM ET Sep 27, 2026
  

  Hutchmed initiates Phase Ia part of global clinical trial of HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors (HK$21.92, 0.00)

• 09:22 PM ET Sep 23, 2026
  

  StreetAccount China Pre Market Update: China ADRs overnight (1.43%); Hang Seng Futures (1.57%)

• 08:20 PM ET Sep 23, 2026
  

  Hutchmed to present new and updated data from several studies of compounds at ESMO 2026 (HK$22.54, 0.00)

• 04:54 PM ET Sep 14, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market